{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:31:12Z","timestamp":1762432272174},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tacrolimus therapy for ulcerative colitis is ineffective in certain patients; these patients require biologics or colectomy. We examined the ability of serum albumin levels and leukocyte subtypes to predict the therapeutic efficacy of tacrolimus. Patients with ulcerative colitis treated with tacrolimus were divided into non-failure and failure (required colectomy or switch to biologics or systemic steroids) groups. Serum albumin levels and leukocyte subtypes at induction, week 1, and week 2 after reaching high trough levels were retrospectively examined. Tacrolimus therapy failed in 18\/45 patients within 3\u00a0months. The week 2\/week 1 albumin ratio was significantly different between the failure and non-failure groups (P\u2009&lt;\u20090.001). The receiver operating characteristic curve analysis revealed optimal cut-off value of the week 2\/week 1 albumin ratio was 1.06, and area under the curve was 0.815. Analysis of leukocyte subtypes revealed significant between-group difference in the week 1 lymphocyte to monocyte ratio (P\u2009&lt;\u20090.001). Multivariate analysis showed week 2\/week 1 albumin ratio\u2009\u2264\u20091.06 and week 1 lymphocyte to monocyte ratio\u2009\u2264\u20093.86. Therefore<jats:bold>,<\/jats:bold> a low week 2\/week 1 albumin and low week 1 lymphocyte to monocyte ratio predicted failure within 3\u00a0months of tacrolimus induction; a combination of these markers could accurately predict failure.<\/jats:p>","DOI":"10.1038\/s41598-022-17763-2","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T13:03:23Z","timestamp":1660050203000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis"],"prefix":"10.1038","volume":"12","author":[{"given":"Natsuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Miyazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"17763_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky, D. K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417\u2013429. https:\/\/doi.org\/10.1056\/NEJMra020831 (2002).","journal-title":"N. Engl. J. Med."},{"key":"17763_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/gut.2005.081794","volume":"55","author":"H Ogata","year":"2006","unstructured":"Ogata, H. et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55, 1255\u20131262. https:\/\/doi.org\/10.1136\/gut.2005.081794 (2006).","journal-title":"Gut"},{"key":"17763_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ibd.21853","volume":"18","author":"H Ogata","year":"2012","unstructured":"Ogata, H. et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflam. Bowel Dis. 18, 803\u2013808. https:\/\/doi.org\/10.1002\/ibd.21853 (2012).","journal-title":"Inflam. Bowel Dis."},{"key":"17763_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2036.2008.03764.x","volume":"28","author":"S Yamamoto","year":"2008","unstructured":"Yamamoto, S. et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment. Pharmacol. Ther. 28, 589\u2013597. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03764.x (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"17763_CR5","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/j.crohns.2013.04.018","volume":"7","author":"J Miyoshi","year":"2013","unstructured":"Miyoshi, J. et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory\/dependent ulcerative colitis patients. J. Crohns Colitis 7, e609\u2013e614. https:\/\/doi.org\/10.1016\/j.crohns.2013.04.018 (2013).","journal-title":"J. Crohns Colitis"},{"key":"17763_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.dld.2015.01.149","volume":"47","author":"K Ikeya","year":"2015","unstructured":"Ikeya, K. et al. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig. Liver Dis. 47, 365\u2013371. https:\/\/doi.org\/10.1016\/j.dld.2015.01.149 (2015).","journal-title":"Dig. Liver Dis."},{"key":"17763_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3162595,3162595","volume":"2016","author":"K Endo","year":"2016","unstructured":"Endo, K. et al. A comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitis. Gastroenterol. Res. Pract. 2016, 1\u201311. https:\/\/doi.org\/10.1155\/2016\/3162595,3162595 (2016).","journal-title":"Gastroenterol. Res. Pract."},{"key":"17763_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462\u20132476. https:\/\/doi.org\/10.1056\/NEJMoa050516 (2005).","journal-title":"N. Engl. J. Med."},{"key":"17763_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257\u201365.e1. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032 (2012).","journal-title":"Gastroenterology"},{"key":"17763_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 85\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048 (2014) (quiz e14\u2013e15).","journal-title":"Gastroenterology"},{"key":"17763_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands, B. E. et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 381, 1215\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa1905725 (2019).","journal-title":"N. Engl. J. Med."},{"key":"17763_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910 (2017).","journal-title":"N. Engl. J. Med."},{"key":"17763_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750 (2019).","journal-title":"N. Engl. J. Med."},{"key":"17763_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.surg.2008.07.005","volume":"144","author":"TA Markel","year":"2008","unstructured":"Markel, T. A. et al. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis. Surgery 144, 540\u2013545. https:\/\/doi.org\/10.1016\/j.surg.2008.07.005 (2008) (discussion 545\u2013547).","journal-title":"Surgery"},{"key":"17763_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/ibd\/izaa309","volume":"27","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Early changes in serum albumin predict clinical and endoscopic outcomes in patients with ulcerative colitis starting anti-TNF treatment. Inflam. Bowel Dis. 27, 1452\u20131461. https:\/\/doi.org\/10.1093\/ibd\/izaa309 (2021).","journal-title":"Inflam. Bowel Dis."},{"key":"17763_CR16","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.3748\/wjg.v27.i22.3109","volume":"27","author":"N Ishida","year":"2021","unstructured":"Ishida, N. et al. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J. Gastroenterol. 27, 3109\u20133120. https:\/\/doi.org\/10.3748\/wjg.v27.i22.3109 (2021).","journal-title":"World J. Gastroenterol."},{"key":"17763_CR17","doi-asserted-by":"publisher","first-page":"e0213505","DOI":"10.1371\/journal.pone.0213505","volume":"14","author":"Y Nishida","year":"2019","unstructured":"Nishida, Y. et al. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS ONE 14, e0213505. https:\/\/doi.org\/10.1371\/journal.pone.0213505 (2019).","journal-title":"PLoS ONE"},{"key":"17763_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12935-018-0698-5","volume":"18","author":"Y Mao","year":"2018","unstructured":"Mao, Y. et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: A meta-analysis. Cancer Cell Int. 18, 201. https:\/\/doi.org\/10.1186\/s12935-018-0698-5 (2018).","journal-title":"Cancer Cell Int."},{"key":"17763_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1097\/MIB.0000000000000427","volume":"21","author":"CE Cherfane","year":"2015","unstructured":"Cherfane, C. E., Gessel, L., Cirillo, D., Zimmerman, M. B. & Polyak, S. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflam. Bowel Dis. 21, 1769\u20131775. https:\/\/doi.org\/10.1097\/MIB.0000000000000427 (2015).","journal-title":"Inflam. Bowel Dis."},{"key":"17763_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13317-019-0114-8","volume":"10","author":"AM Okba","year":"2019","unstructured":"Okba, A. M. et al. Neutrophil\/lymphocyte ratio and lymphocyte\/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Auto Immun. Highlights 10, 4. https:\/\/doi.org\/10.1186\/s13317-019-0114-8 (2019).","journal-title":"Auto Immun. Highlights"},{"key":"17763_CR21","doi-asserted-by":"publisher","first-page":"6517549","DOI":"10.1155\/2019\/6517549","volume":"2019","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Correlation between serological biomarkers and disease activity in patients with inflammatory bowel disease. BioMed. Res. Int. 2019, 6517549. https:\/\/doi.org\/10.1155\/2019\/6517549 (2019).","journal-title":"BioMed. Res. Int."},{"key":"17763_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0016-5085(73)80030-7","volume":"64","author":"DB Sachar","year":"1973","unstructured":"Sachar, D. B. et al. Imparied lymphocyte responsiveness in inflammatory bowel disease. Gastroenterology 64, 203\u2013209 (1973).","journal-title":"Gastroenterology"},{"key":"17763_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1042\/cs0690241","volume":"69","author":"A Hermanowicz","year":"1985","unstructured":"Hermanowicz, A. et al. The role of phagocytes in inflammatory bowel disease. Clin. Sci. 69, 241\u2013249. https:\/\/doi.org\/10.1042\/cs0690241 (1985).","journal-title":"Clin. Sci."},{"key":"17763_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clinre.2012.06.004","volume":"36","author":"S Torun","year":"2012","unstructured":"Torun, S. et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity. Clin. Res. Hepatol. Gastroenterol. 36, 491\u2013497. https:\/\/doi.org\/10.1016\/j.clinre.2012.06.004 (2012).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"17763_CR25","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1053\/j.gastro.2011.02.047","volume":"140","author":"TT MacDonald","year":"2011","unstructured":"MacDonald, T. T. et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140, 1768\u20131775. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.047 (2011).","journal-title":"Gastroenterology"},{"key":"17763_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ibd\/izab031","volume":"28","author":"A Anderson","year":"2022","unstructured":"Anderson, A. et al. Monocytosis is a biomarker of severity in inflammatory bowel disease: Analysis of a 6-year prospective natural history registry. Inflamm. Bowel Dis. 28, 70\u201378. https:\/\/doi.org\/10.1093\/ibd\/izab031 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"17763_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/ecco-jcc\/jjx118","volume":"12","author":"A Nakarai","year":"2018","unstructured":"Nakarai, A. et al. Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. J. Crohns Colitis 12, 71\u201376. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx118 (2018).","journal-title":"J. Crohns Colitis"},{"key":"17763_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.cgh.2019.07.054","volume":"18","author":"M Naganuma","year":"2020","unstructured":"Naganuma, M. et al. Significance of conducting 2 types of fecal tests in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 18, 1102-1111.e5. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.054 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"17763_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3892\/etm.2016.3341","volume":"12","author":"H Ban","year":"2016","unstructured":"Ban, H. et al. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp. Ther. Med. 12, 829\u2013834. https:\/\/doi.org\/10.3892\/etm.2016.3341 (2016).","journal-title":"Exp. Ther. Med."},{"key":"17763_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/clpt.2010.348","volume":"89","author":"KR Herrlinger","year":"2011","unstructured":"Herrlinger, K. R. et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin. Pharmacol. Ther. 89, 422\u2013428. https:\/\/doi.org\/10.1038\/clpt.2010.348 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"17763_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro, F. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohns Colitis 11, 649\u2013670. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx008 (2017).","journal-title":"J. Crohns Colitis"},{"key":"17763_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 298, 82\u201386. https:\/\/doi.org\/10.1136\/bmj.298.6666.82 (1989).","journal-title":"BMJ"},{"key":"17763_CR33","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625\u20131629. https:\/\/doi.org\/10.1056\/NEJM198712243172603 (1987).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17763-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:50:18Z","timestamp":1669359018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17763-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17763"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17763-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"6 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13572"}}